Close mobile menu×
Close mobile menu

Garrett Lawlor, MD

Expertise in: 
Gastroenterology
Accepting New Patients
Profile Headshot

Schedule an Appointment

Phone Appointments

New and Existing Patients:

Connect Patient Portal

For existing patients, login to make an appointment, view documentation or contact your care provider.

Connect Sign In

Credentials & Experience

Clinical Expertise

  • Crohns Disease
  • Inflammatory Bowel Diseases (IBD)
  • Ulcerative Colitis

Education & Training

  • University College Dublin School of Medicine
  • Residency: Mater Misericordiae University Hospital, Dublin
  • Fellowship: Beth Israel Deaconess Medical Center

About Garrett Lawlor

Garrett Lawlor, MD, is the associate director of the inflammatory bowel disease program. Dr. Lawlor went to medical school at University College Dublin and completed his residency and GI fellowship at the Mater Misericordiae University Hospital in Dublin. He then moved to Boston, where he underwent a two-year, advanced fellowship in inflammatory bowel diseases at the IBD center at Beth Israel Deaconess Medical Center. There he conducted clinical, translational, and basic lab research on clinical, molecular, and genetic markers of disease activity and response to therapy in patients with IBD.

Dr. Lawlor subsequently worked on the Brooklyn campus of the NY Harbor Veterans Affairs System, where as director of inflammatory bowel diseases, he set up a tertiary referral service for veterans in the Northeast suffering from IBD. As assistant director of the SUNY Downstate GI fellowship program, he promoted clinical and translational research, studying alterations in the gut microbiome in patients undergoing antibiotic therapy for C difficile-related diarrhea. He is secretary of the New York Crohn’s and Colitis Organization. He has published widely on etiological mechanisms and management options in Crohn’s disease and ulcerative colitis, celiac disease, and colon cancer. He welcomes physician referrals for IBD, IBD trials, refractory C diff diarrhea, and general GI.

Academic Titles

  • Assistant Professor of Medicine at CUMC

Administrative Positions

  • Associate Director, Inflammatory Bowel Disease Program

Hospital Affiliations

  • NewYork-Presbyterian / Columbia University Irving Medical Center

Gender

  • Male

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NYP Employee Plan
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Essential Plan
  • Medicaid Managed Care

AgeWell

  • Medicare Managed Care
  • Special Needs Plan

Amida Care

  • Special Needs Plan

Capital District Physician Health Plan

  • Capital District Physician Health Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Elderplan

  • Medicare Managed Care

Emblem/GHI

  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • EPO
  • Medicare Managed Care
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Leaf (Exchange)
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Medicare

  • Traditional Medicare (NY)

Multiplan

  • Multiplan

MVP Health Care

  • Child/Family Health Plus
  • Essential Plan
  • HMO
  • Medicaid Managed Care

Oxford Health Plans

  • Freedom
  • Liberty

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth
  • Special Needs Plan

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
161 Fort Washington Avenue
Suite 862
New York, New York 10032
Primary
2
51 West 51st Street
New York, New York 10019

Research

Grants

APHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PLATFORM STUDY EVALUATING THE EFFICACY AND SAFETY OF INTERVENTIONS IN PARTICIPANTS WITH MODERATELY TOSEVERELY ACTIVE CROHN'S DISEASE (P&S Industry Clinical Trial)

Apr 23 2020 - Apr 23 2025

THE PRECIOUS STUDY: PREDICTING CROHN'S & COLITIS OUTCOMES IN THE UNITED STATES (P&S Industry Clinical Trial)

Jan 3 2020 - Jan 3 2025

ECO-RESET: A PHASE 2B, RANDOMIZED DOUBLE- BLIND PLACEBO- CONTROLEED MULTIPLE DOSE MULTICENTER STUDY TO ASSESS EFFICACY AND SAFETY OF SER-287 IN ADULTS WITH ACTIVE MILD TO MODERATE ULCERATIVE COLITIS (P&S Industry Clinical Trial)

Apr 24 2019 - Apr 24 2024

ANOPEN LABEL, LONG TERM SAFETY TRIAL OF BI 655130 TREATMENT IN PATIENTS WITH MODERATE TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO HAVE COMPLETED PREVIOUS BI 655130 TRIALS. (P&S Industry Clinical Trial)

Dec 10 2018 - Dec 10 2023

APHASE 3, MULTICENTER, OPEN-LABEL, EXTENSION STUDY TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (P&S Industry Clinical Trial)

Nov 27 2018 - Nov 27 2023

AMULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MAINTENANCE AND LONG-TERM EXTENSION STUDY OF THE EFFICACY AND SAFETY OF UPADACITINIB (ABT-494) IN SUBJECTS WITH CROHN'S DISEASE WHO COMPLETED THE STUDIES M14-431 OR M14-433 (P&S Industry Clinical Trial)

Jul 5 2018 - Jul 5 2023

APHASE II/III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BI 655130 INDUCTION THERAPY IN PATIENTS WITH MODERATE-TO-SEVERELY ACTIVE ULCERATIVE COLITIS WHO HAVE FAILED PREVIOUS BIOLOGICS (P&S Industry Clinical Trial)

Jul 3 2018 - Jul 3 2023

AMULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION STUDY OF THE EFFICACY, SAFETY OF UPADACITINIB (ABT-494) IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE (P&S Industry Clinical Trial)

Jul 1 2018 - Jul 1 2023

AMULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION STUDY OF THE EFFICACY AND SAFETY OF UPADACITINIB (ABT-494) IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE. (P&S Industry Clinical Trial)

Jul 1 2018 - Jul 1 2023

AMULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RISANKIZUMAB IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO HAVE FAILED PRIOR BIOLOGIC THERAPY (P&S Industry Clinical Trial)

Jun 12 2018 - Jun 12 2023

AMULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 52-WEEK MAINTENANCE AND AN OPEN-LABEL EXTENSION STUDY OF THE EFFICACY AND SAFETY OF RISANKIZUMAB IN SUBJECTS WITH ULCERATIVE COLITIS WHO RESPONDED TO INDUCTION TREATMENT IN M16-067 OR M16-065 (P&S Industry Clinical Trial)

Jun 8 2018 - Jun 8 2023

AMULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ABT-494 FOR INDUCTION AND MAINTENANCE THERAPY IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (P&S Industry Clinical Trial)

May 1 2018 - May 1 2023

AMULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION STUDY TO ASSESS THE EFFICACY AND SAFETY OF RISANKIZUMAB IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO FAILED PRIOR BIOLOGIC TREATMENT. (P&S Industry Clinical Trial)

Apr 27 2018 - Apr 27 2023

APHASE 3 MULTICENTER, OPEN-LABEL EXTENSION (OLE) STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF ABT-494 IN SUBJECTS WITH ULCERATIVE COLITIS (UC). (P&S Industry Clinical Trial)

Apr 27 2018 - Apr 27 2023

MULTICENTER,RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION STUDY OF THE EFFICACY AND SAFETY OF RISANKIZUMAB IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE. (P&S Industry Clinical Trial)

Apr 20 2018 - Apr 20 2023

AMULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 52-WEEK MAINTENANCE AND AN OPEN-LABEL EXTENSION STUDY OF THE EFFICACY AND SAFETY OF RISANKIZUMAB IN SUBJECTS WITH CROHN'S DISEASE WHO RESPONDED TO INDUCTION TREATMENT IN M16-006 OR M15-991 (P&S Industry Clinical Trial)

Jun 19 2018 - Jun 19 2022

ADVANCED IBD FELLOWSHIP (Private)

Jul 1 2020 - Jun 30 2021

IBD FELLOW SUPPORT (Private)

Jul 1 2020 - Jun 30 2021

APHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER PROTOCOL TO EVALUATE THE SAFETY AND EFFICACY OF USTEKINUMAB INDUCTION AND MAINTENANCE THERAPY IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (P&S Industry Clinical Trial)

Mar 24 2016 - Mar 24 2021

SAPPHIRE - IBD (Private)

Mar 23 2016 - Mar 22 2017